» Authors » Molly C McCloskey

Molly C McCloskey

Explore the profile of Molly C McCloskey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 279
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleming J, McCloskey M, Gray K, Nash D, Leung V, Michas C, et al.
Curr Res Toxicol . 2025 Feb; 8:100218. PMID: 39944108
Animal models of the neuromuscular junction (NMJ) have been widely studied but exhibit critical differences from human biology limiting utility in drug and disease modelling. Challenges with scarcity, scalability, throughput,...
2.
McCloskey M, Ahmad S, Widom L, Kasap P, Gastfriend B, Shusta E, et al.
Biomater Res . 2024 Oct; 28():0081. PMID: 39363889
Sepsis is the most lethal and expensive condition treated in intensive care units. Sepsis survivors frequently suffer long-term cognitive impairment, which has been linked to the breakdown of the blood-brain...
3.
McCloskey M, Kasap P, Trempel M, Widom L, Kuebel J, Chen K, et al.
J Vis Exp . 2024 Jan; 203. PMID: 38284519
The microSiM (µSiM) is a membrane-based culture platform for modeling the blood-brain barrier (BBB). Unlike conventional membrane-based platforms, the µSiM provides experimentalists with new capabilities, including live cell imaging, unhindered...
4.
Hudecz D, McCloskey M, Vergo S, Christensen S, McGrath J, Nielsen M
Int J Mol Sci . 2023 Mar; 24(6. PMID: 36982697
Understanding the vesicular trafficking of receptors and receptor ligands in the brain capillary endothelium is essential for the development of the next generations of biologics targeting neurodegenerative diseases. Such complex...
5.
Hulverson M, Choi R, Schaefer D, Betzer D, McCloskey M, Whitman G, et al.
Antimicrob Agents Chemother . 2023 Mar; 67(4):e0142522. PMID: 36920244
Recent advances on the development of bumped kinase inhibitors for treatment of cryptosporidiosis have focused on the 5-aminopyrazole-4-carboxamide scaffold, due to analogs that have less hERG inhibition, superior efficacy, and...
6.
Su S, Song Y, Stephens A, Situ M, McCloskey M, McGrath J, et al.
Biosens Bioelectron . 2023 Jan; 224():115030. PMID: 36603283
Organ-on-a-chip platforms have potential to offer more cost-effective, ethical, and human-resembling models than animal models for disease study and drug discovery. Particularly, the Blood-Brain-Barrier-on-a-chip (BBB-oC) has emerged as a promising...
7.
McCloskey M, Zhang V, Ahmad S, Walker S, Romanick S, Awad H, et al.
Front Med Technol . 2022 Dec; 4():979768. PMID: 36483299
The vascular system plays a critical role in the progression and resolution of inflammation. The contributions of the vascular endothelium to these processes, however, vary with tissue and disease state....
8.
Mansouri M, Ahmed A, Ahmad S, McCloskey M, Joshi I, Gaborski T, et al.
Adv Healthc Mater . 2022 Aug; 11(21):e2200802. PMID: 35953453
Microfluidic tissue barrier models have emerged to address the lack of physiological fluid flow in conventional "open-well" Transwell-like devices. However, microfluidic techniques have not achieved widespread usage in bioscience laboratories...
9.
McCloskey M, Kasap P, Ahmad S, Su S, Chen K, Mansouri M, et al.
Adv Healthc Mater . 2022 Jul; 11(18):e2200804. PMID: 35899801
Advanced in vitro tissue chip models can reduce and replace animal experimentation and may eventually support "on-chip" clinical trials. To realize this potential, however, tissue chip platforms must be both...
10.
Salminen A, McCloskey M, Ahmad S, Romanick S, Chen K, Houlihan W, et al.
Eur J Cell Biol . 2022 May; 101(3):151233. PMID: 35605366
Sphingosine-1-phosphate (S1P) signals to enhance or destabilize the vascular endothelial barrier depending on the receptor engaged. Here, we investigated the differential barrier effects of S1P on two influential primary endothelial...